Should I Buy BEAM? BEAM 2026 Analysis

Should You Buy Beam Therapeutics Inc (BEAM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

29.290

1 Day change

0.93%

52 Week Range

36.440

Analysis Updated At

2026/01/28

Not a good buy right now for a Beginner, long-term investor who is impatient. Despite supportive Wall Street targets and bullish options positioning, BEAM’s near-term momentum is weakening (bearish MACD), insiders have recently been heavy sellers, and fundamentals remain loss-making with declining revenue. With no Intellectia buy signals today, the risk/reward is not compelling enough to buy immediately at $28.96; better to wait for momentum to stabilize or for Q1’26 AATD data to confirm upside.

Technical Analysis

Price/Trend: BEAM is down -5.83% in the regular session to $28.96 (small pre-market bounce +1.63%), and is trading very close to S2 support at 28.81 (S1 at 30.316; Pivot at 32.753). Momentum: MACD histogram -0.174 and negatively expanding indicates bearish/weakening momentum near-term. RSI(6) ~45.25 is neutral, not signaling an oversold bounce. Moving Averages: The moving-average structure is bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader trend has been constructive, but the current pullback is challenging that trend. Key levels: If 28.81 breaks, downside risk increases; upside recovery would first need to reclaim ~30.32 (S1) and then the pivot ~32.75 to reassert strength. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment read: Options positioning is notably call-heavy (low put/call ratios on both open interest and volume), which is typically bullish sentiment. Activity/volatility: Today’s options volume (1,800) is elevated vs the 30-day average (~117.65%), and open interest is also elevated vs average (~138.97%), suggesting active positioning. Implied volatility 30D (~50.73) is well below historical volatility (~79.08) and IV percentile is very low (2), implying options are relatively cheap versus recent realized movement—often a constructive setup for bullish positioning, but it does not override weakening spot momentum today.

Technical Summary

Sell

Buy

Positive Catalysts

Pipeline catalyst setup into Q1 2026: multiple analysts highlight updated Alpha-1 Antitrypsin Deficiency (AATD) / BEAM-302 data in Q1’26 as crucial.
Analyst actions are supportive: multiple Outperform/Buy ratings with raised price targets following a positive regulatory update on the AATD program.
Flow/support: Hedge funds are buying (reported buying amount up +161.22% QoQ), a constructive signal for institutional interest.
Options sentiment: Call-heavy positioning (very low put/call ratios) suggests bullish trader sentiment.

Neutral/Negative Catalysts

Insider activity is a key negative: insiders are selling (selling amount up +980.39% over the last month), which can weigh on sentiment.
Near-term technicals deteriorating: bearish/expanding negative MACD and sharp -5.83% session drop with price sitting near critical support (~28.81).
Short-horizon pattern odds: the provided pattern study suggests a negative next-month bias (-3.12%).
No fresh news in the past week to counter the current selloff with a near-term catalyst.

Financial Performance

Latest reported quarter: 2025/Q3. Revenue: $9.70M, down -32.03% YoY (weak top-line trend). Profitability: Net income improved YoY to -$112.73M (still a large loss), implying slightly better cost control vs prior year but still deeply unprofitable. EPS: -$1.10, down -5.98% YoY (slightly worse per-share loss). Overall growth trend: revenue is shrinking and losses remain significant, consistent with a development-stage biotech profile rather than stable long-term compounding fundamentals.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: analyst sentiment is broadly positive with multiple Outperform/Buy ratings and several price target increases/initiations into late 2025 and January 2026. Key changes: - 2026-01-20 Bernstein: Outperform, PT raised to $41 (from $37) on positive regulatory update; highlights Q1’26 AATD data as key. - 2026-01-06 BofA: Buy, PT raised to $45 (from $43). - 2025-11-24 Evercore ISI: Outperform, PT $35 (initiation), calls BEAM-302 potentially game-changing; Q1’26 data crucial. - 2026-01-07 UBS: Neutral, PT $28 (more cautious vs others). Wall Street pros vs cons: Pros—strong catalyst calendar (AATD/BEAM-302 data) and generally bullish coverage/targets. Cons—at least one major neutral view (UBS) near current price, and the stock remains a pre-commercial biotech where execution/data risk dominates; insider selling also undercuts the bullish narrative. Influential/politician activity: No recent congress trading data available in the last 90 days; no politician activity provided.

13 Analyst Rating

Wall Street analysts forecast BEAM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAM is 42 USD with a low forecast of 21 USD and a high forecast of 80 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

3 Hold

0 Sell

Strong Buy

Current: 29.020

Low

Averages

High

Current: 29.020

Low

Averages

High

Bernstein

Outperform

maintain

$37 -> $41

AI Analysis

2026-01-20

Reason

Bernstein

Price Target

$37 -> $41

AI Analysis

2026-01-20

maintain

Outperform

Reason

Bernstein raised the firm's price target on Beam Therapeutics to $41 from $37 and keeps an Outperform rating on the shares. The firm raised its price target following last week's positive regulatory update on the Alpha-1 Antitrypsin Deficiency program. While Last week's regulatory event was the main 2026 stock catalyst the firm was playing for, there are still several important events to track through the year end, including updated AATD data in Q126, the analyst tells investors in a research note.

UBS

Michael Yee

Neutral

initiated

$28

2026-01-07

Reason

UBS

Michael Yee

Price Target

$28

2026-01-07

initiated

Neutral

Reason

UBS analyst Michael Yee initiated coverage of Beam Therapeutics (BEAM) with a Neutral rating and $28 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BEAM

Unlock Now

BEAM Should I Buy

BEAM Should I Buy

Should You Buy Beam Therapeutics Inc (BEAM) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch